Close this search box.

Mills to step down as RegenxBio CEO, becomes chair

ARTICLE | Management Tracks

Plus: Harald Reinhart retires at Zai Lab and updates from Skyhawk, Crossject, Neurona and Coulter Partners

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst 

June 12, 2024 7:24 PM UTC

Kenneth Mills will step down as president and CEO of  RegenxBio Inc. (NASDAQ:RGNX) to become chair on July 1. COO Curran Simpson will succeed Mills, who co-founded the AAV gene therapy company in 2009. RegenxBio also named board member Daniel Tassé as lead independent director, a role previously held by Jerry Karabelas. Karabelas will remain on the board, as will co-founder and outgoing Chair Allan Fox.

Harald Reinhart will retire from  Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) as head of global development for neuroscience, autoimmune and infectious diseases and become senior adviser. Rafael Amado, president and head of global oncology R&D, will lead global R&D upon Reinhart’s retirement as president, head of global R&D…